Up to 80% of the plasma from blood collections can be replaced by PAS III M Grifols.
- Saved plasma can be used for transfusion or fractionation into plasma derivatives
- Decrease of adverse reactions associated with plasma transfusion
Composition designed to maintain platelet viability up to 7 days*
- Reduces platelet activation
- Prevents platelet aggregation
- Reduces platelet metabolism
- Maintains membrane stability
- Improves functionality of platelets
- Maintains pH
Compatible with all technologies to prepare platelet concentrates
- PAS III M Grifols can be used together with automated devices for buffy-coat and apheresis derived platelets
- PAS III M Grifols can be used together with any pathogen reduction technology
*When the European recommendation of the "Guide to the Preparations, Use and Quality Assurance of Blood Components" is followed and the applicable local legislation and the validation of the blood component preparation do not restrict it.